Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMP001 (tarenflurbil) in relapsing-remitting multiple sclerosis
2014-004483-38Phase 2Completed
- Sponsor
- Fraunhofer-Gesellschaft
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarenflurbil in relapsing-remitting multiple sclerosis (RRMS), sponsored by Fraunhofer-Gesellschaft. Primary endpoint: Average total number of contrast-enhancing lesions. Started Apr 2015; status: completed.
02
Drugs
tarenflurbil
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2014-004483-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004483-38.